These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16378067)

  • 21. Resolution of severe atopic dermatitis after tacrolimus withdrawal.
    Ponte GM; Baidal DA; Romanelli P; Faradji RN; Poggioli R; Cure P; Froud T; Selvaggi G; Pileggi A; Ricordi C; Alejandro R
    Cell Transplant; 2007; 16(1):23-30. PubMed ID: 17436852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the effect of immunosuppression on engraftment of pancreatic islets.
    Vallabhajosyula P; Hirakata A; Shimizu A; Okumi M; Tchipashvili V; Hong H; Yamada K; Sachs DH
    Transplantation; 2013 Aug; 96(4):372-8. PubMed ID: 23883972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of the female reproductive system in islet recipient receiving immunosuppression.
    Del Olmo Garcia MI; Lauriola V; Aracena AG; Messinger S; Corrales A; Ricordi C; Alejandro R
    Cell Transplant; 2011; 20(10):1649-51. PubMed ID: 21396172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective effect of glucocorticoid-free immunosuppressive regimen in allogenic islet transplantation.
    Du CY; Xu EK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):43-7. PubMed ID: 16481281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.
    Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P
    Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts.
    Jaeger C; Brendel MD; Hering BJ; Eckhard M; Bretzel RG
    Diabetes; 1997 Nov; 46(11):1907-10. PubMed ID: 9356046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunosuppression after solitary islet transplantation is associated with preserved C-peptide secretion for more than a decade.
    Blau JE; Abegg MR; Flegel WA; Zhao X; Harlan DM; Rother KI
    Am J Transplant; 2015 Nov; 15(11):2995-3001. PubMed ID: 26184712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients.
    Scharp DW; Lacy PE; Santiago JV; McCullough CS; Weide LG; Boyle PJ; Falqui L; Marchetti P; Ricordi C; Gingerich RL
    Transplantation; 1991 Jan; 51(1):76-85. PubMed ID: 1987709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
    Posselt AM; Szot GL; Frassetto LA; Masharani U; Tavakol M; Amin R; McElroy J; Ramos MD; Kerlan RK; Fong L; Vincenti F; Bluestone JA; Stock PG
    Transplantation; 2010 Dec; 90(12):1595-601. PubMed ID: 20978464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
    J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts.
    Hilbrands R; Gillard P; Van der Torren CR; Ling Z; Verheyden S; Jacobs-Tulleneers-Thevissen D; Roep BO; Claas FH; Demanet C; Gorus FK; Pipeleers D; Keymeulen B
    Transplantation; 2013 Jul; 96(2):162-9. PubMed ID: 23857001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
    Posselt AM; Bellin MD; Tavakol M; Szot GL; Frassetto LA; Masharani U; Kerlan RK; Fong L; Vincenti FG; Hering BJ; Bluestone JA; Stock PG
    Am J Transplant; 2010 Aug; 10(8):1870-80. PubMed ID: 20659093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients.
    Hilbrands R; Huurman VA; Gillard P; Velthuis JH; De Waele M; Mathieu C; Kaufman L; Pipeleers-Marichal M; Ling Z; Movahedi B; Jacobs-Tulleneers-Thevissen D; Monbaliu D; Ysebaert D; Gorus FK; Roep BO; Pipeleers DG; Keymeulen B
    Diabetes; 2009 Oct; 58(10):2267-76. PubMed ID: 19602536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial.
    Maffi P; Berney T; Nano R; Niclauss N; Bosco D; Melzi R; Mercalli A; Magistretti P; De Cobelli F; Battaglia M; Scavini M; Demuylder-Mischler S; Secchi A; Piemonti L
    Transplantation; 2014 Dec; 98(12):1301-9. PubMed ID: 25286053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation.
    Freise CE; Kang SM; Feng S; Posselt A; Hirose K; Hirose R; Stock P
    Transplant Proc; 2004 May; 36(4):1067-8. PubMed ID: 15194370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppression for pancreatic islet transplantation.
    Berney T; Buhler LH; Majno P; Mentha G; Morel P
    Transplant Proc; 2004 Mar; 36(2 Suppl):362S-366S. PubMed ID: 15041369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.
    Montero N; Webster AC; Royuela A; Zamora J; Crespo Barrio M; Pascual J
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD007669. PubMed ID: 25220222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transplant Proc; 2005 Mar; 37(2):1326-7. PubMed ID: 15848711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.